• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2373-9436
    Volume 6, Issue 2
    Research Article
    Razmik Mirzayans*, Bonnie Andrais, and David Murray
    Solid tumors and solid tumor-derived cell lines typically contain a small proportion of giant cells with a highly enlarged nucleus or multiple nuclei. Although giant cells enter a state of dormancy and cease to proliferate, they exhibit resistance to anticancer agents, secrete growth-promoting factors, and can give rise to progeny with stem cell-like properties that can repopulate the tumor. In the present study we determined the response of the MDA-MB-231 breast carcinoma cell line to chemotherapeutic drugs in terms of proliferation, morphology and metabolic activity. We report that treatment with moderate (non-toxic) concentrations of oxaliplatin (=10 µM) or paclitaxel (=20 nM) triggers proliferation arrest which largely reflects the development of giant cells that remain adherent to the culture dish, retain viability, and exhibit the ability to convert 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) to its water insoluble formazan metabolite. The single-cell MTT assay demonstrated that the metabolic activity per cell is much higher (>3 times) in drug-treated cultures, which are enriched with giant cells, than in sham-treated controls. These results give credence to a growing body of evidence suggesting that targeting dormant cancer cells could be a critical strategy for minimizing the chance of relapse following conventional cancer treatment.
    SP Suchitra*, R Nagarathna, and HR Nagendra
    Background: Ayurveda asserts that, the increase or decrease in the status of tridosha (Vata, Pitta, Kapha) is the cause for the manifestation of all the diseases. Cancer is explained as Arbuda and vata and kapha vriddhi (increase) is referred as cause by Ayurveda classics. Studies are available on the relationship between prakrti (constitution) of an individual and diseases. No studies are available on vitiation of tridosha.
    Method: Design of the study was descriptive type. Sampling design was purposive sampling. Tridosha diagnosis scale (TDS), interviewer based, which consists 97 items: for Vtaja vriddhi, 14 items for Vata kshaya: 16 items for Pittaja vriddhi, 11 items for Pitta Kshaya: 20 items for Kaphaja vriddhi and 15 items for Kapha kshaya: was developed which had reliability above 0.7 for all subscales of TDS. TDS was administered on 5 cancer patients, (three were lung cancer, two were of liver cancer) recruited from Arogyadhama hospital of SVYASA university, Bangalore.
    Results: It was found that, there were more vata vriddhi and kapha vriddhi laskhanas in cancer patients (more than 40%) in both vata vriddhi and kapha vriddhi scales. Conclusions: The present study has given good basis for further study on larger samples to confirm statistically the findings of study which may in turn may point for specific plan and diet regime based on tridosha.
    Raju Vivek*
    The breast cancer is a disease in which malignant cells form in the tissues of the breast and leading to death among the woman in worldwide. Early detection of breast cancer is a challenging to the breast cancer therapeutics, because of the different patterns of the breast cancers includes, Hormone receptor-positive (ER+ and/or PR+), Receptor HER2-positive; and Triple-negative breast cancer (TNBCs) types. These ER+, PR+ and HER2+ marker proteins also serve as breast cancer therapeutic targets of specific therapeutics. Tumors with none of these ER-, PR-, HER2- are known as TNBCs. In this review, the author deliberated the current status, different types of breast cancers, risk factors associated with breast cancers, treatment strategies, and side effects of the breast cancer treatments. At the end of this review overall future outlook of the breast cancer treatments and its future nanoparticles, peptides and PROTACs - based therapeutic approaches are well discussed.
  • Current Issue Highlights
  • BRAT1 was originally identified as a BRCA1 interacting protein [1], however, subsequent studies showed that it also binds to ATM, DNA-PK, and SMC1,

    Mechanisms of detecting and repairing damaged DNA are conserved and controlled through the DNA damage response (DDR).

    JSciMed Central Peer-reviewed Open Access Journals
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.